Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy

Bibliography

• HOFFMAN EP BRJ, KUNKEL LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell (1987) 51:919-928.
   PubMed Web of Science ®Google Scholar
• KANAGAWA M, TODA T: The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis. J. Hum Genet. (2006) 51:915-926.
   PubMed Web of Science ®Google Scholar
• HOFFMAN EP, FISCHBECK KH, BROWN RH et al.: Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne’s or Becker’s muscular dystrophy. N. Engl. J. Med. (1988) 318:1363-1368.
   PubMed Web of Science ®Google Scholar
• KOENIG M, MONACO AP, KUNKEL LM: The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell (1988) 53:219-228.
   PubMed Web of Science ®Google Scholar
• KOENIG M, HOFFMAN EP, BERTELSON CJ, MONACO AP, FEENER C, KUNKEL LM: Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell (1987) 50:509-517.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN JS, PEARLMAN JA, MUZNY DM et al.: Expression of the murine Duchenne muscular dystrophy gene in muscle and brain. Science (1988) 239:1416-1418.
   PubMed Web of Science ®Google Scholar
• NUDEL U, ROBZYK K, YAFFE D: Expression of the putative Duchenne muscular dystrophy gene in differentiated myogenic cell cultures and in the brain. Nature (1988) 331:635-638.
   PubMed Web of Science ®Google Scholar
• WELLER B, KARPATI G, CARPENTER S: Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions.J. Neurol. Sci. (1990) 100:9-13.
   PubMed Web of Science ®Google Scholar
• YANG B, JUNG D, MOTTO D,MEYER J, KORETZKY G, CAMPBELL KP: SH3 domain-mediated interaction of dystroglycan and Grb2. J. Biol. Chem. (1995) 270:11711-11714.
   PubMed Web of Science ®Google Scholar
• BRENMAN JE, CHAO DS, XIA H, ALDAPE K, BREDT DS: Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell (1995) 82:743-752.
   PubMed Web of Science ®Google Scholar
• YOKOTA T, HOSAKA Y, TSUKITA K et al.: Aquaporin-4 is absent at the sarcolemma and at perivascular astrocyte endfeet in alpha1-syntrophin knockout mice. Proc. Japan Acad. (2000) 76B:22-27.
   Google Scholar
• LOVE DR, BYTH BC, TINSLEY JM, BLAKE DJ, DAVIES KE: Dystrophin and dystrophin-related proteins: a review of protein and RNA studies. Neuromuscul. Disord. (1993) 3:5-21.
   PubMed Web of Science ®Google Scholar
• KOENIG M, BEGGS AH, MOYER M et al.: The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet. (1989) 45:498-506.
   PubMed Web of Science ®Google Scholar
• AMANN KJ, RENLEY BA, ERVASTI JM: A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. J. Biol. Chem. (1998) 273:28419-28423.
   PubMed Web of Science ®Google Scholar
• SAKAMOTO M, YUASA K, YOSHIMURA M et al.: Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem. Biophys. Res. Commun. (2002) 293:1265-1272.
   PubMed Web of Science ®Google Scholar
• HEALD A, ANDERSON LV, BUSHBY KM, SHAW PJ: Becker muscular dystrophy with onset after 60 years. Neurology (1994) 44:2388-2390.
   PubMed Web of Science ®Google Scholar
• WILTON SD, DYE DE,BLECHYNDEN LM, LAING NG: Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy? Neuromuscul. Disord. (1997) 7:329-335.
   PubMed Web of Science ®Google Scholar
• CRAWFORD GE, LU QL,PARTRIDGE TA, CHAMBERLAIN JS: Suppression of revertant fibers in mdx mice by expression of a functional dystrophin. Hum. Mol. Genet. (2001) 10:2745-2750.
   PubMed Web of Science ®Google Scholar
• FANIN M, DANIELI GA, VITIELLO L, SENTER L, ANGELINI C: Prevalence of dystrophin-positive fibers in 85 Duchenne muscular dystrophy patients. Neuromuscul. Disord. (1992) 2:41-45.
   PubMed Web of Science ®Google Scholar
• HOFFMAN EP, MORGAN JE, WATKINS SC, PARTRIDGE TA: Somatic reversion/suppression of the mouse mdx phenotype in vivo. J. Neurol. Sci. (1990) 99:9-25.
   PubMed Web of Science ®Google Scholar
• NICHOLSON LV, DAVISON K, JOHNSON MA et al.: Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy. J. Neurol. Sci. (1989) 94:137-146.
   PubMed Web of Science ®Google Scholar
• LU QL, MORRIS GE, WILTON SD et al.: Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J. Cell Biol. (2000)148:985-996.
   PubMed Web of Science ®Google Scholar
• DIETZ HC, KENDZIOR RJ JR: Maintenance of an open reading frameas an additional level of scrutiny during splice site selection. Nat. Genet. (1994) 8:183-188.
   PubMed Web of Science ®Google Scholar
• NAYLOR J, BRINKE A, HASSOCK S, GREEN PM, GIANNELLI F: Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions. Hum. Mol. Genet. (1993) 2:1773-1778.
   PubMed Web of Science ®Google Scholar
• YOKOTA T, LU QL, MORGAN JE et al.: Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. J. Cell. Sci. (2006) 119:2679-2687.
   PubMed Web of Science ®Google Scholar
• WILTON SD, FLETCHER S: Modification of pre-mRNA processing: application to dystrophin expression. Curr. Opin. Mol. Ther. (2006) 8:130-135.
   PubMed Web of Science ®Google Scholar
• FLETCHER S, HONEYMAN K, FALL AM, HARDING PL,JOHNSEN RD, WILTON SD: Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J. Gene Med. (2006) 8:207-216.
   PubMed Web of Science ®Google Scholar
• ALTER J, LOU F, RABINOWITZ A et al.: Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. (2006) 12:175-177.
   PubMed Web of Science ®Google Scholar
• PRAMONO ZA, TAKESHIMA Y, ALIMSARDJONO H, ISHII A, TAKEDA S, MATSUO M: Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem. Biophys. Res. Commun. (1996) 226:445-449.
   PubMed Web of Science ®Google Scholar
• AARTSMA-RUS A, JANSON AA, KAMAN WE et al.: Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am. J. Hum. Genet. (2004) 74:83-92.
   PubMed Web of Science ®Google Scholar
• WELLS DJ: Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy. J. Muscle Res. Cell. Motil. (2006) 27:387-398.
   PubMed Web of Science ®Google Scholar
• MELIS MA, CAU M, MUNTONI F et al.: Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur. J. Paediatr. Neurol. (1998) 2:255-261.
   PubMedGoogle Scholar
• SCHWARTZ M, DUNO M, PALLE AL, KRAG T, VISSING J: Deletion of exon 16 of the dystrophin gene is not associated with disease. Hum. Mutat. (2007) 28:205.
   PubMedGoogle Scholar
• LU QL MC, LOU F, BOU-GHARIOS G et al.: Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. (2003) 9:1009-1014.
   PubMed Web of Science ®Google Scholar
• SUMMERS JS, SHAW BR: Boranophosphates as mimics of natural phosphodiesters in DNA. Curr. Med. Chem. (2001) 8:1147-1155.
   PubMed Web of Science ®Google Scholar
• KOIZUMI M: ENA oligonucleotides as therapeutics. Curr. Opin. Mol. Ther. (2006) 8:144-149.
   PubMed Web of Science ®Google Scholar
• OPALINSKA JB, GEWIRTZ AM: Rationally targeted, conformationally constrained, oxetane-modified oligonucleotides demonstrate efficient gene-silencing activity in acellular system. Ann. NY Acad. Sci. (2005) 1058:39-51.
   PubMed Web of Science ®Google Scholar
• KARKARE S, BHATNAGAR D: Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino. Appl. Microbiol. Biotechnol. (2006) 71:575-586.
   PubMed Web of Science ®Google Scholar
• HORIE M, MORITA K, KAWAKAMI J, ANDO O, KOIZUMI M, TSUTSUMI S: Comparison between properties of2′-O,4′-C-ethylene-bridged nucleic acid (ENA) phosphorothioate oligonucleotides and N3′-P5′ thiophosphoramidate oligonucleotides. Nucleosides Nucleotides Nucleic Acids (2006) 25:231-242.
   PubMed Web of Science ®Google Scholar
• WILSON C, KEEFE AD: Building oligonucleotide therapeutics using non-natural chemistries. Curr. Opin. Chem. Biol. (2006) 10:607-614.
   PubMed Web of Science ®Google Scholar
• CHIANG MY, CHAN H, ZOUNES MA, FREIER SM, LIMA WF, BENNETT CF: Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. (1991) 266:18162-18171.
   PubMed Web of Science ®Google Scholar
• LU QL, RABINOWITZ A, CHEN YC et al.: Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. USA (2005) 102:198-203.
   PubMed Web of Science ®Google Scholar
• MONIA BP, LESNIK EA,GONZALEZ C et al.: Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. (1993) 268:14514-14522.
   PubMed Web of Science ®Google Scholar
• AARTSMA-RUS A, KAMAN WE, BREMMER-BOUT M et al.: Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene. Ther. (2004) 11:1391-1398.
   PubMed Web of Science ®Google Scholar
• SUMMERTON J, WELLER D: Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. (1997) 7:187-195.
   PubMedGoogle Scholar
• McCLOREY G, MOULTON HM, IVERSEN PL, FLETCHER S, WILTON SD: Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. (2006) 13(19):1373-1381.
   PubMedGoogle Scholar
• HUDZIAK RM, BAROFSKY E, BAROFSKY DF, WELLER DL, HUANG SB, WELLER DD: Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. (1996) 6:267-272.
   PubMedGoogle Scholar
• CARTEGNI L, CHEW SL, KRAINER AR: Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. (2002) 3:285-298.
   PubMed Web of Science ®Google Scholar
• POWELL C, SHANSKY J, DEL TATTO M et al.: Tissue-engineered human bioartificial muscles expressing a foreign recombinant protein for gene therapy. Hum. Gene Ther. (1999) 10:565-577.
   PubMed Web of Science ®Google Scholar
• JANSON AA, GINJAAR IH, AARTSMA-RUS A et al.: Antisense-induced exon skipping in Duchenne muscular dystrophy patients. Neuromuscul. Disord. (2006) 16:722.
   Google Scholar
• MUNTONI F, BUSHBY K, VAN OMMEN G: 128th ENMC International Workshop on ‘Preclinical optimization and Phase I/II clinical trials using antisense oligonucleotidesin Duchenne muscular dystrophy’ 22-24 October 2004, Naarden, The Netherlands. Neuromuscul. Disord. (2005) 15:450-457.
   PubMedGoogle Scholar
• DENT KM, DUNN DM, VON NIEDERHAUSERN AC et al.: Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am. J. Med. Genet. A (2005) 134:295-298.
   PubMedGoogle Scholar
• WHITE SJ, AARTSMA-RUS A, FLANIGAN KM et al.: Duplications in the DMD gene. Hum. Mutat. (2006) 27:938-945.
   PubMed Web of Science ®Google Scholar
• FALL AM, JOHNSEN R,HONEYMAN K, IVERSEN P, FLETCHER S, WILTON SD: Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet. Vaccines Ther. (2006) 4:3.
   PubMedGoogle Scholar
• BEROUD C, TUFFERY-GIRAUD S, MATSUO M et al.: Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum. Mutat. (2007) 28:196-202.
   PubMed Web of Science ®Google Scholar
• KOENIG M, KUNKEL LM: Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J. Biol. Chem. (1990) 265:4560-4566.
   PubMed Web of Science ®Google Scholar
• ARAKI E, NAKAMURA K, NAKAO Ket al.: Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. Biochem. Biophys. Res. Commun. (1997) 238:492-497.
   PubMed Web of Science ®Google Scholar
• IM WB, PHELPS SF, COPEN EH, ADAMS EG, SLIGHTOM JL, CHAMBERLAIN JS: Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum. Mol. Genet. (1996) 5:1149-1153.
   PubMed Web of Science ®Google Scholar
• YUGETA N, URASAWA N, FUJII Y et al.: Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies. BMC Cardiovasc. Disord. (2006) 6:47.
   PubMedGoogle Scholar
• WANG X, LIANG HD, DONG B, LU QL, BLOMLEY MJ: Gene transfer with microbubble ultrasound and plasmid DNA into skeletal muscle of mice: comparison between commercially available microbubble contrast agents. Radiology (2005) 237:224-229.
   PubMed Web of Science ®Google Scholar
• VANNAN M, MCCREERY T, LI P et al.: Ultrasound-mediated transfection of canine myocardium by intravenous administration of cationic microbubble-linked plasmid DNA. J. Am. Soc. Echocardiogr. (2002) 15:214-218.
   PubMed Web of Science ®Google Scholar
• GOYENVALLE A, VULIN A, FOUGEROUSSE F et al.: Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.Science (2004) 306:1796-1799.
   PubMed Web of Science ®Google Scholar